Drugs / anti-SARS-CoV-2 convalescent plasma
anti-SARS-CoV-2 convalescent plasma
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04345679 | Apr 2020 → Jun 2021 | COVID-19 | Orthosera Kft. | Unknown | No outcome recorded |
| Phase 0 | NCT04340050 | Apr → Dec 2020 | Coronaviridae infectious disease | University of Chicago | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04354831 | May 2020 → Feb 2021 | COVID-19 | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04567173 | Sep 2020 → Jun 2021 | COVID-19 | University of the Philippines | Terminated | No outcome recorded |
| Phase 2/3 | NCT04425837 | Jul 2020 → Feb 2021 | COVID-19 | Fundación Santa Fe de Bogota | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04432103 | Aug 2020 → Jan 2021 | COVID-19 | Centro Medico ABC | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04397523 | Apr 2020 → May 2021 | COVID-19 | Institute for Transfusion Medicine of RNM | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04360486 Background | — | COVID-19 | U.S. Army Medical Research and Development Command | No longer available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-SARS-CoV-2 convalescent plasma | “This is a Phase II/III randomized clinical trial to assess the effectiveness and safety of anti-SARS-CoV-2 convalescent plasma in i) hospitalized adult patients with high-risk...” NCT04425837 ↗ |
| Known as | ASCoV2CP | “Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)” NCT04360486 ↗ |
| Known as | CCP | “COVID-19 convalescent plasma (CCP) is an important antiviral option for selected patients with COVID-19.” PMID 36295001 ↗ Oct 2022 |
| Known as | COVID-19 convalescent plasma | “COVID-19 convalescent plasma (CCP) is an important antiviral option for selected patients with COVID-19.” PMID 36295001 ↗ Oct 2022 |
| Modality | Protein / enzyme biologic | “Plasma transfusion of convalescent patients from COVID-19 with negative RT-PCR, and antibody titers of 1:160 or greater” NCT04425837 ↗ |
| Route | Intravenous | “through an iv. infusion of 4 hours” NCT04345679 ↗ |